Pretransplant MRD: The light is yellow, not red

摘要

In the study reported in this issue of Blood by Leung et al, detectable minimal residual disease (MRD) before hematopoietic stem cell transplantation (HSCT) was found to be prognostic for outcome, but did not prevent cure for children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).